195 related articles for article (PubMed ID: 15780373)
1. Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study.
Urakami S; Yoshino T; Kikuno N; Imai S; Honda S; Yoneda T; Kishi H; Shigeno K; Shiina H; Igawa M
Urology; 2005 Mar; 65(3):543-8. PubMed ID: 15780373
[TBL] [Abstract][Full Text] [Related]
2. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer.
Kikuno N; Urakami S; Nakamura S; Hiraoka T; Hyuga T; Arichi N; Wake K; Sumura M; Yoneda T; Kishi H; Shigeno K; Shiina H; Igawa M
Eur Urol; 2007 May; 51(5):1252-8. PubMed ID: 17208356
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer.
Matsumoto A; Inoue A; Yokoi S; Nozumi K; Miyazaki K; Hosoki S; Nagata M; Yamaguchi K
Int J Urol; 2009 Aug; 16(8):687-91. PubMed ID: 19602005
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer.
Yasufuku T; Shigemura K; Matsumoto O; Arakawa S; Fujisawa M
J Infect Chemother; 2010 Jun; 16(3):200-5. PubMed ID: 20221782
[TBL] [Abstract][Full Text] [Related]
6. A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy.
Mizota A; Shitara K; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Muro K
Oncology; 2011; 81(3-4):237-42. PubMed ID: 22094594
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
Oh WK; Hagmann E; Manola J; George DJ; Gilligan TD; Jacobson JO; Smith MR; Kaufman DS; Kantoff PW
Clin Cancer Res; 2005 Jan; 11(1):284-9. PubMed ID: 15671557
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer.
Sella A; Yarom N; Zisman A; Kovel S
Oncology; 2009; 76(6):442-6. PubMed ID: 19420966
[TBL] [Abstract][Full Text] [Related]
9. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.
Hudes GR; Nathan FE; Khater C; Greenberg R; Gomella L; Stern C; McAleer C
Semin Oncol; 1995 Oct; 22(5 Suppl 12):41-5. PubMed ID: 7481860
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer.
Safarinejad MR
Urol Oncol; 2005; 23(2):93-101. PubMed ID: 15869993
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients.
Nakagami Y; Ohori M; Sakamoto N; Koga S; Hamada R; Hatano T; Tachibana M
Int J Urol; 2010 Jul; 17(7):629-34. PubMed ID: 20438593
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
Solit DB; Morris M; Slovin S; Curley T; Schwartz L; Larson S; Kattan MW; Hartley-Asp B; Scher HI; Kelly WK
Cancer; 2003 Nov; 98(9):1842-8. PubMed ID: 14584065
[TBL] [Abstract][Full Text] [Related]
15. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.
Nakabayashi M; Sartor O; Jacobus S; Regan MM; McKearn D; Ross RW; Kantoff PW; Taplin ME; Oh WK
BJU Int; 2008 Feb; 101(3):308-12. PubMed ID: 18184327
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel and docetaxel in prostate cancer.
Obasaju C; Hudes GR
Hematol Oncol Clin North Am; 2001 Jun; 15(3):525-45. PubMed ID: 11525295
[TBL] [Abstract][Full Text] [Related]
17. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
[TBL] [Abstract][Full Text] [Related]
18. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
Picus J; Schultz M
Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
